← Leaderboards
Zefeng Wang
Univ Of North Carolina Chapel Hill
$1,770,661
Attributed
$1,770,661
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $466.3K · FY2011–15$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$1,770,661 · 2
By mechanism
R01$1,412,215 · 1
R21$358,446 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Victoria L. Bautch$17,850,903
- John Christopher Chappell$3,451,472
- Dirk P Dittmer$32,603,888
- Kathleen M Caron$16,068,293
- Suk-Won Jin$3,875,368
Others in their field
Top investigators on “Spliced Genes”
- Rolf Apweiler · European Molecular Biology Laboratory$41,336,566
- David H Haussler · University Of California Santa Cruz$35,921,482
- Daniel H Geschwind · University Of California Los Angeles$35,212,697
- Stacey Gabriel · Massachusetts Institute Of Technology$30,450,662
- Adrian R Krainer · Cold Spring Harbor Laboratory$28,797,786
- Susan E Celniker · University Of Calif-Lawrenc Berkeley Lab$28,763,902
Research focus
Spliced GenesEngineeringProteinsGenesAnimal ModelMessenger RnaDesignMolecularSiteStagingAffectRna SplicingBaseAlternative SplicingAdultCellsBevacizumabAntisense OligonucleotidesAntiangiogenesis TherapyEquilibriumExonsCause Of DeathAnimalsCancer Therapy
Grant awards (7)
Modulation of VEGF-A alternative splicing as new anti-angiogenic therapeutics$300,803
R01 · FY2015 · CA · contact PI
Modulation of VEGF-A alternative splicing as new anti-angiogenic therapeutics$291,898
R01 · FY2014 · CA · contact PI
Modulation of VEGF-A alternative splicing as new anti-angiogenic therapeutics$278,486
R01 · FY2013 · CA · contact PI
Modulation of VEGF-A alternative splicing as new anti-angiogenic therapeutics$270,456
R01 · FY2012 · CA · contact PI
Artificial site-specific RNA endonuclease as new Myotonic Dystrophy therapeutics$195,834
R21 · FY2012 · AR · contact PI
Modulation of VEGF-A alternative splicing as new anti-angiogenic therapeutics$270,572
R01 · FY2011 · CA · contact PI
Artificial site-specific RNA endonuclease as new Myotonic Dystrophy therapeutics$162,612
R21 · FY2011 · AR · contact PI